重组抗人CD20单抗(B9E9) | Syd Labs PA007456
体内实验级重组抗人CD20单克隆抗体，小鼠IgG2a Kappa（克隆号:B9E9，Syd Labs货号：PA007456）是用哺乳动物细胞生产的重组抗体，适用于体外和体内研究，纯度>95%。其不变区为小鼠Mouse IgG2a Kappa (mIgG2a或m2a)，可与重组小鼠IgG2a同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007456 |
|---|---|
| 产品名称 | 重组抗人CD20单抗(B9E9) | Syd Labs PA007456 |
| 英文名 | In vivo Grade Recombinant Anti-Human CD20 Monoclonal Antibody, Mouse IgG2a Kappa (Clone: B9E9) |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | B 淋巴细胞抗原 CD20、B 淋巴细胞表面抗原 B1、Bp35、白细胞表面抗原 Leu-16、跨膜 4 结构域亚家族 A 成员 1、CD 抗原 CD20、CD20 |
| 概述 | Syd Labs提供重组小鼠IgG2a同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | B9E9 |
| 同种型 | 小鼠 IgG2a kappa |
| 应用 | ELISA、流式细胞术、中和、功能测定，如生物分析PK和ADA测定，以及用于研究受人CD20蛋白影响的生物途径的测定。 |
| 免疫源 | 重组抗人CD20单克隆抗体（克隆：B9E9）在哺乳动物细胞中产生 |
| 抗体形式 | 0.2 μM过滤溶液，1x PBS |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗人CD20单克隆抗体，小鼠IgG2a Kappa(克隆号B9E9) 用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 自收到之日起 1 个月，保存在2 至 8°C。 自收到之日起12个月，保存在-20 至 -70°C。 |
| 注意事项 | PA007456 Syd Labs提供重组小鼠IgG2a同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | ELISA、流式细胞术、中和、功能测定，如生物分析PK和ADA测定，以及用于研究受人CD20蛋白影响的生物途径的测定。 |
文献
抗人CD20单克隆抗体 ，体内实验级重组，小鼠IgG2a Kappa(克隆号B9E9)（In vivo Grade Recombinant Anti-Human CD20 Monoclonal Antibody, Mouse IgG2a Kappa (Clone: B9E9)，货号：PA007456 Syd Labs）
抗人CD20单抗（克隆号B9E9）是B细胞生物学及体液免疫机制研究中广泛使用的靶向试剂。CD20作为表达于前B细胞至成熟B细胞表面的非糖基化跨膜磷蛋白，在调节B细胞激活、增殖、分化及跨膜钙离子流中发挥关键作用。B9E9抗体能够特异性结合人CD20分子的胞外域，常用于评估B细胞清除机制、诱导补体依赖性细胞毒性（CDC）与抗体依赖性细胞介导的细胞毒性（ADCC），以及探究非霍奇金淋巴瘤、慢性淋巴细胞白血病和自身免疫性疾病的免疫学病理过程。
Syd Labs提供的重组抗人CD20单抗（B9E9，Mouse IgG2a Kappa，体内实验级）采用高表达哺乳动物细胞系统重组制备，有效克服了传统杂交瘤表达易变异、批间差大及夹杂内源性杂质蛋白的缺点。产品具备极高的纯度与良好的批间稳定性，严格控制内毒素水平，且无载体蛋白与有毒防腐剂，非常适合敏感的体内（in vivo）和体外（in vitro）功能研究。此外，该抗体可与Syd Labs重组Mouse IgG2a同型对照抗体配套使用，为生物医药研发与B细胞免疫学研究提供科学严谨、高重复性的可靠实验数据支撑。
抗人CD20单抗(B9E9)部分引用文献:
1. Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity
Morita, D., et al. J Immunother Cancer. 2024 Dec 9;12(12):e009741. PMID: 39653552
“Fluorochrome-conjugated monoclonal antibodies, including anti-human CD20 (clone B9E9), were used to stain human cells for flow cytometry analysis with Gallios or BD FACSymphony cytometers at Texas Children’s Hospital. Eight weeks post-injection, PBMCs from humanized mice were stained with anti-human CD45 to confirm humanization. Other antibodies, such as anti-CD3 (UCHT1), CD4 (SK3), and CD8 (RPA-T8), were used to assess immune cell profiles, demonstrating T-cell redirection for enhanced antitumor immunity.”
Morita, D., et al. J Immunother Cancer. 2024 Dec 9;12(12):e009741. PMID: 39653552
“Fluorochrome-conjugated monoclonal antibodies, including anti-human CD20 (clone B9E9), were used to stain human cells for flow cytometry analysis with Gallios or BD FACSymphony cytometers at Texas Children’s Hospital. Eight weeks post-injection, PBMCs from humanized mice were stained with anti-human CD45 to confirm humanization. Other antibodies, such as anti-CD3 (UCHT1), CD4 (SK3), and CD8 (RPA-T8), were used to assess immune cell profiles, demonstrating T-cell redirection for enhanced antitumor immunity.”
2. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma
Forero, A., et al. Blood. 2004 Jul 1;104(1):227-36. PMID: 14996706
“A phase 1 trial assessed the safety, pharmacokinetics, and immunogenicity of a tetrameric single-chain anti-CD20-streptavidin fusion protein (B9E9FP) in patients with B-cell non-Hodgkin lymphoma (NHL) for pretargeted radioimmunotherapy (PRIT). The B9E9FP (anti-human CD20) targeted HLA class I/peptide complexes, showing in vivo activity when combined with anti-viral T cells, supporting further clinical development with autologous CTLs from vaccination or ex vivo expansion.”
Forero, A., et al. Blood. 2004 Jul 1;104(1):227-36. PMID: 14996706
“A phase 1 trial assessed the safety, pharmacokinetics, and immunogenicity of a tetrameric single-chain anti-CD20-streptavidin fusion protein (B9E9FP) in patients with B-cell non-Hodgkin lymphoma (NHL) for pretargeted radioimmunotherapy (PRIT). The B9E9FP (anti-human CD20) targeted HLA class I/peptide complexes, showing in vivo activity when combined with anti-viral T cells, supporting further clinical development with autologous CTLs from vaccination or ex vivo expansion.”
3. An oncolytic measles virus engineered to enter cells through the CD20 antigen
Bucheit, A. D., et al. Mol Ther. 2003 Jan;7(1):62-72. PMID: 12573619
“An oncolytic measles virus (MV) was engineered to enter CD20(+) target cells via a single-chain (scFv) anti-CD20 antibody (B9E9) interaction with the CD20 antigen in non-Hodgkin’s lymphoma (NHL) models. The virus demonstrated enhanced oncolytic activity in vivo against CD20(+) tumors, showing equivalent effects on CD20(-) tumors, highlighting the clinical relevance of B9E9 (anti-human CD20) for targeted viral therapy.”
Bucheit, A. D., et al. Mol Ther. 2003 Jan;7(1):62-72. PMID: 12573619
“An oncolytic measles virus (MV) was engineered to enter CD20(+) target cells via a single-chain (scFv) anti-CD20 antibody (B9E9) interaction with the CD20 antigen in non-Hodgkin’s lymphoma (NHL) models. The virus demonstrated enhanced oncolytic activity in vivo against CD20(+) tumors, showing equivalent effects on CD20(-) tumors, highlighting the clinical relevance of B9E9 (anti-human CD20) for targeted viral therapy.”
4. Anti-viral cytotoxic T cells inhibit the growth of cancer cells with antibody targeted HLA class I/peptide complexes in SCID mice
Savage, P., et al. Int J Cancer. 2002 Apr 1;98(4):538-44. PMID: 11920616
“The B9E9 scFvSA fusion protein (anti-human CD20) targeted HLA-A2/M1 complexes to Daudi cells, enabling CTL-mediated killing in vitro at dilutions as low as 100 pg/ml. In vivo SCID mouse assays showed that only one of four mice receiving B9E9 scFvSA, HLA-A2/M1 complexes, and anti-HLA-A2/M1 CTLs developed a tumor, supporting clinical development with autologous CTLs.”
Savage, P., et al. Int J Cancer. 2002 Apr 1;98(4):538-44. PMID: 11920616
“The B9E9 scFvSA fusion protein (anti-human CD20) targeted HLA-A2/M1 complexes to Daudi cells, enabling CTL-mediated killing in vitro at dilutions as low as 100 pg/ml. In vivo SCID mouse assays showed that only one of four mice receiving B9E9 scFvSA, HLA-A2/M1 complexes, and anti-HLA-A2/M1 CTLs developed a tumor, supporting clinical development with autologous CTLs.”
5. Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes
Savage, P., et al. Br J Cancer. 2002 Apr 22;86(8):1336-42. PMID: 11953895
“The B9E9 scFvSA fusion protein (anti-human CD20 mAb) delivered HLA-A2/class I peptide complexes to HLA class I-negative Daudi cells. Flow cytometry confirmed retention of targeted HLA-A2/M1 complexes, and in vitro CTL responses were observed in PBMCs pre-treated with B9E9 scFvSA. The B9E9 fusion protein, currently in clinical trials for B-cell lymphoma with radiolabeled biotin, demonstrated effective targeting for CTL induction.”
Savage, P., et al. Br J Cancer. 2002 Apr 22;86(8):1336-42. PMID: 11953895
“The B9E9 scFvSA fusion protein (anti-human CD20 mAb) delivered HLA-A2/class I peptide complexes to HLA class I-negative Daudi cells. Flow cytometry confirmed retention of targeted HLA-A2/M1 complexes, and in vitro CTL responses were observed in PBMCs pre-treated with B9E9 scFvSA. The B9E9 fusion protein, currently in clinical trials for B-cell lymphoma with radiolabeled biotin, demonstrated effective targeting for CTL induction.”